244 related articles for article (PubMed ID: 21575046)
1. Livedo reticularis: a side effect of interferon therapy in a pediatric patient with melanoma.
Fox M; Tahan S; Kim CC
Pediatr Dermatol; 2012; 29(3):333-5. PubMed ID: 21575046
[TBL] [Abstract][Full Text] [Related]
2. Livedo reticularis associated with interferon alpha therapy in two melanoma patients.
Ruiz-Genao DP; García-F-Villalta MJ; Hernández-Núñez A; Ríos-Buceta L; Fernández-Herrera J; García-Díez A
J Eur Acad Dermatol Venereol; 2005 Mar; 19(2):252-4. PubMed ID: 15752306
[TBL] [Abstract][Full Text] [Related]
3. Nursing management of patients with malignant melanoma receiving adjuvant alpha interferon-2b.
Kiley KE; Gale DM
Clin J Oncol Nurs; 1998 Jan; 2(1):11-6. PubMed ID: 9481251
[TBL] [Abstract][Full Text] [Related]
4. Grand mal seizure induced by interferon-alpha-2b.
Kors C; Milling A; Hofmann M; Sterry W; Trefzer U
J Eur Acad Dermatol Venereol; 2006 Apr; 20(4):473-4. PubMed ID: 16643159
[No Abstract] [Full Text] [Related]
5. Early signs of liver failure after low-dose interferon alfa-2b for cutaneous melanoma.
Ammoury A; El Sayed F; Farah C; Bazex J
J Am Acad Dermatol; 2008 Mar; 58(3):532-3. PubMed ID: 18280369
[No Abstract] [Full Text] [Related]
6. [Vitiligo and morphea: autoimmune cutaneous side effects of interferon treatment].
Martínez-García S; Fernández-Ballesteros MD; Segura-Palacios JM
Actas Dermosifiliogr; 2012 Apr; 103(3):250-1. PubMed ID: 22056259
[No Abstract] [Full Text] [Related]
7. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.
Nishihori T; Abdo-Matkiwsky M; Fleishman SB; Blum RH
Am J Clin Oncol; 2005 Oct; 28(5):526. PubMed ID: 16199995
[TBL] [Abstract][Full Text] [Related]
8. Lipoatrophy associated with interferon alfa adjuvant therapy for melanoma.
Vallés L; González M; Polo I; Enguita AB; Vanaclocha F; Ortiz-Romero PL
Arch Dermatol; 2009 Jan; 145(1):98-9. PubMed ID: 19153363
[No Abstract] [Full Text] [Related]
9. Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon-α.
Zonta E; Chiarion V; Zarian H; Peserico A; Alaibac M
Melanoma Res; 2012 Jun; 22(3):284-5. PubMed ID: 22543678
[No Abstract] [Full Text] [Related]
10. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
Guillot B; Blazquez L; Bessis D; Dereure O; Guilhou JJ
Dermatology; 2004; 208(1):49-54. PubMed ID: 14730237
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.
Enudi W; Udolu OJ
Afr J Psychiatry (Johannesbg); 2009 Aug; 12(3):227-8. PubMed ID: 19750253
[TBL] [Abstract][Full Text] [Related]
12. [Ocular complications of adjuvant interferon therapy for malignant melanoma: a review].
Ockenfels M; Lisch W
Hautarzt; 2003 Feb; 54(2):144-7. PubMed ID: 12590309
[TBL] [Abstract][Full Text] [Related]
13. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
Lawson BO; Khong HT
Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304
[TBL] [Abstract][Full Text] [Related]
14. Interstitial pneumonitis in a patient with melanoma treated with the high dose interferon alpha 2b regimen.
Siegelmann-Danieli N; Bardo M; Law A; Fisk D; Bernath A
Isr Med Assoc J; 2004 Oct; 6(10):636-7. PubMed ID: 15473596
[No Abstract] [Full Text] [Related]
15. Urticaria, angioedema and dyspnoea in adjuvant therapy of melanoma with interferon alpha-2b.
Helbig D; Simon JC; Treudler R
Acta Derm Venereol; 2010 May; 90(3):308-9. PubMed ID: 20526557
[No Abstract] [Full Text] [Related]
16. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous sarcoidosis by interferon therapy in a patient with melanoma.
Alonso-Pérez A; Ballestero-Díez M; Fraga J; García-Díez A; Fernández-Herrera J
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1328-9. PubMed ID: 17062055
[No Abstract] [Full Text] [Related]
18. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
[TBL] [Abstract][Full Text] [Related]
19. High-dose adjuvant interferon therapy for melanoma.
Licata AG
Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
[TBL] [Abstract][Full Text] [Related]
20. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Rot U; Ledinek AH
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S79-81. PubMed ID: 24321162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
